Can a new drug shrink Hard-to-Treat adrenal tumors?
NCT ID NCT07743138
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare cancers will receive ivonescimab by IV. The main goals are to see if the drug is safe and to measure its effect on tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab (given by IV)
- What this could lead to
- If ivonescimab proves effective, it could offer a new treatment option for people with advanced adrenal cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase study, so the drug may not work as hoped or may cause significant side effects. Results will need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo tame aggressive appendiceal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- New drug combo aims to shrink oral cancers before surgery
- New drug imetelstat targets rare blood cancer in phase 2 trial
- New hope for rare kidney cancer: drug trial targets tough tumors
- New drug combo shows promise in shrinking esophageal tumors before surgery